BMS’ Breyanzi and Amgen’s Blincyto will now be available to patients in England with certain types of blood cancer.

The patient remains NED for follicular lymphoma, with no recurrence detected in the latest CT scan. A declining immunoglobulin factor is noted, but it currently poses no health concerns. Stable lymph ...

Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has issued Final Draft Guidance ...

NICE's initial guidance on Breyanzi concluded it was not a cost-effective option for patients, but the agency said this ...

Baidu, Inc. (NASDAQ:BIDU) retreated on Tuesday, losing 7.51 percent to close at $90.16 apiece as investors unloaded ...

Tempus AI (TEM) stock surged 13.4% on Thursday, hitting a new 52-week high of $86. The upside came after the health ...

We recently published a list of 10 Stocks Kick Off Trading Week With Losses. In this article, we are going to take a look at ...

Nancy Pelosi just made Tempus AI (TEM) the stock of the moment. The former Speaker of the House quietly purchased 50 call ...

With positive mid-stage results in marginal zone lymphoma, Bristol Myers Squibb could soon add a new indication for the CAR T ...

Tempus AI, Inc. (NASDAQ:TEM) stock is trading higher on Thursday after the company announced a collaboration with the ...

Tempus AI shares soared to an all-time high Thursday as the tech firm announced a collaboration with the nonprofit Institute ...